The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
January 20, 2025
View Complete Issue         Table of Contents 2019 
Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
January 20, 2025 (Issue: 1720)
Zanidatamab-hrii (Ziihera – Jazz), a bispecific HER2-directed antibody, has received accelerated approval from the FDA for treatment of unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer in patients who received prior...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
Article code: 1720f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.